[1] HAGENBUCH B，MEIER P J. The superfamily of organic anion transporting polypeptides[J] .Biochim Biophys Acta，2003，1609(1):1-18. [2] KOBAYASHI D，NOZAWA T，IMAI K，et al. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane[J] .J Pharmacol Exp Ther，2003，306(2): 703-708. [3] CVETKOVIC M，LEAKE B，FROMM M F，et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine[J] .Drug Metab Dispos，1999，27(8): 866-871. [4] PERLOFF M D，VON MOLTKE L L，GREENBLATT D J. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir[J] .J Clin Pharmacol，2002，42(11): 1269. [5] Allegra(fexofenadine) Prescribing Information. Physician's Desk Reference[M] . Montvale(NJ): Medical Economics，2000，1343-1344. [6] MEREDITH D，BOYD C A. Structure and function of eukaryotic peptide transporters[J] .Cell Mol Life Sci，2000，57(5): 754-778. [7] PANG H，TU J S. The function and application of drug transport protein[J] .Pharm Biotech(药物生物技术)，2005，12(1): 62-65. [8] ZHANG X H，SONG J G. Transport mechanism of β-lactam antibiotics in intestine and kindney[J] .Chin J Clin Pharmacol Ther(中国临床药理学与治疗学)，2003，8(3): 252-254. [9] BERGAN T. Pharmacokinetic properties of the cephalosporins[J] . Drugs，1987，34(Suppl 2): 89-104. [10] HU M，SUBRAMANIAN P，MOSBERG H I，et al. Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics，intestinal permeabilities，and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa[J] .Pharm Res，1989，6(1): 66-70. [11] BALIMANE P V，TAMAI I，GUO A，et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug，valacyclovir[J] .Biochem Biophys Res Commun，1998，250(2): 246-251. [12] NARUHASHI K，SAI Y，TAMAI I，et al. PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine[J] .Pharm Res，2002，19(10): 1417-1423. [13] CHU X Y，SANCHEZ-CASTANO G P，HIGAKI K，et al. Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter[J] .J Pharmacol Exp Ther，2001，299(2): 575-582. [14] WIJNHOLDS J，DE LANGE E C，SCHEFFER G L，et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier[J] .J Clin Invest，2000，105(3): 279-285. [15] JOHNSON D R， FINCH R A， LIN Z P， et al. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice[J] .Cancer Res，2001，61(4): 1469-1476. [16] MARZOLINI C，PAUS E，BUCLIN T，et al. Polymorphisms in human MDR1(P-glycoprotein): recent advances and clinical relevance[J] .Clin Pharmacol Ther，2004，75(1): 13-33. [17] DAI C L，FU L W.The development of the reversal of the tumor multidrug resistance[J] .Chin Pharmacol Bull(中国药理学通报)，2005，21(5):513-518. [18] LAN K，JIANG X H.Advance in search for p-glycoprotein and its inhibitors[J] .Chin Pharm(中国药房)，2005，16(10):787-790. [19] STEPHENS R H，O'NEILL C A，BENNETT J，et al. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice[J] .Br J Pharmacol，2002，135(8): 2038-2046. [20] BARDELMEIJER H A，BEIJNEN J H，BROUWER K R，et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein[J] .Clin Cancer Res，2000，6(11)：4416-4421. [21] MEERUM TERWOGT J M，MALINGRE M M，BEIJNEN JH，et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel[J] .Clin Cancer Res，1999，5(11): 3379-3384. [22] BATES S E，BAKKE S，KANG M，et al. A phase Ⅰ/Ⅱ study of infusional vinblastine with the P-glycoprotein antagonist valspodar(PSC833) in renal cell carcinoma[J] .Clin Cancer Res，2004，10(14): 4724-4733. [23] SABABI M，BORGA O，HULTKVIST-BENGTSSON U. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats[J] .Eur J Pharm Sci，2001，14(1): 21-27. [24] MASUDA S，UEMOTO S，HASHIDA T，et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient[J] .Clin Pharmacol Ther，2000，68(1): 98-103. [25] LOWN K S，MAYO R R，LEICHTMAN AB，et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine[J] .Clin Pharmacol Ther，1997，62(3): 248-260. [26] HOFFMEYER S，BURK O，von RICHTER O，et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J] .Proc Natl Acad Sci USA，2000，97(7): 3473-3478. [27] HITZL M，DRESCHER S，VAN DER KUIP H，et al. The C3435T mutation in the human MDR1gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells[J] .Pharmacogenetics，2001，11(4): 293-298. [28] GREINER B，EICHELBAUM M，FRITZ P，et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin[J] .J Clin Invest，1999，104(2): 147-153. [29] PISCITELLI S C，BURSTEIN A H，CHAITT D，et al. Indinavir concentrations and St John's wort[J] .Lancet，2000，355(9203): 547-548. [30] DRESSER G K，SCHWARZ U I，WILKINSON G R，et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects[J] .Clin Pharmacol Ther，2003，73(1): 41-50. [31] EDWARDS D J，FITZSIMMONS M E，SCHUETZ E G，et al. 6'，7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition，enterocyte CYP3A4，and P-glycoprotein[J] .Clin Pharmacol Ther，1999，65(3): 237-244. [32] SPAHN-LANGGUTH H，LANGGUTH P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol[J] .Eur J Pharm Sci，2001，12(4): 361-367. [33] GOTOH Y，SUZUKI H，KINOSHITA S，et al. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats[J] .J Pharmacol Exp Ther，2000，292(1): 433-439. [34] CHEN Z Y，XU L G. Research advances in drug transporters and multidrug resistance[J] .Chin Oncol(中国癌症杂志)，2003，13(6):582-586. [35] SPARREBOOM A，DANESI R，ANDO Y，et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy[J] .Drug Resist Updat，2003，6(2):71-84. [36] KRUIJTZER C M，BEIJNEN J H，ROSING H，et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918[J] .J Clin Oncol，2002，20(13): 2943-2950. [37] JONKER J W，SMIT J W，BRINKHUIS R F，et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan[J] .J Natl Cancer Inst，2000，92(20): 1651-1656.